PRNewsWire
19 Aug 2026, 06:43 UTC · 1h ago
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
19 Aug 2026, 06:43 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics faces a securities fraud lawsuit alleging it failed to disclose that the FDA had not agreed to changes in the statistical analysis plan for Deramiocel before BLA resubmission. — Lack of FDA alignment on clinical data analysis significantly increases the risk of regulatory rejection for the company's primary cell therapy candidate.
-0.80The lawsuit claims there is a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — Directly threatens the commercial viability of a key product pipeline, which is a primary driver of valuation for biotech firms.
-0.70A class action lawsuit has been filed on behalf of investors who purchased CAPR securities between December 17, 2025, and July 26, 2026. — Legal proceedings create financial liability and overhead, though the merit of the claims is still to be determined in court.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities fraud class action lawsuit alleging misleading statements regarding clinical data and FDA approval risks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
